PW Medtech Group (1358) investor relations material

Executive summary

• Revenue for the six months ended June 30, 2026 was RMB394.1 million, down 4.9% year-over-year, mainly due to price declines in the Infusion Set Business from expanded centralized procurement.

• Gross profit fell 10.8% to RMB189.9 million, with gross margin dropping to 48.2% from 51.3% a year earlier.

• Profit attributable to owners was RMB14.7 million, a 77.7% decrease year-over-year; adjusted net profit attributable to owners was RMB31.3 million, down 62.5%.

• Interim dividend declared at HK1.1 cents per share, compared to HK4.4 cents in the prior year.

Financial highlights

• Blood Purification Business revenue rose 3.7% to RMB308.5 million, offsetting some decline in Infusion Set Business, which dropped 29.1% to RMB80.4 million.

• Regenerative Medical Biomaterials Business revenue increased 46.3% to RMB5.2 million.

• Adjusted net profit for the period was RMB68.6 million, down 42.4% year-over-year.

• Operating profit decreased 54.9% to RMB36.2 million.

• Net finance income fell 36.2% to RMB14.6 million.

Outlook and guidance

• The company will continue to focus on innovation-driven growth, optimizing product mix, and expanding R&D investment.

• Plans to further develop high-value infusion products and expand the blood purification product line, including peritoneal dialysis.

• Will leverage technological leadership in regenerative biomaterials and expand sales network.

• Management expects continued pressure on prices and margins due to centralized procurement but aims to offset with operational efficiency and product innovation.